Skip to main content
Erschienen in: CNS Drugs 7/2010

01.07.2010 | Review Article

Antidepressant-induced hyperprolactinaemia

incidence, mechanisms and management

verfasst von: Flora Coker, Prof. David Taylor

Erschienen in: CNS Drugs | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Prolactin, a polypeptide hormone, is responsible, amongst other things, for milk production during lactation and breast enlargement during pregnancy. Numerous drugs can affect prolactin levels. Most commonly, conventional antipsychotics are associated with hyperprolactinaemia but there have also been reports of antidepressants causing hyperprolactinaemia. This review sets out to establish the incidence of antidepressant-induced hyperprolactinaemia, its possible mechanism and to determine appropriate remedial actions. Nearly all antidepressants are reported to be associated with hyperprolactinaemia. Incidence rates were not clearly established and symptoms were very rare. The mechanism by which antidepressants may cause hyperprolactinaemia is not fully understood, though several theories have been postulated, such as serotonin stimulation of GABAergic neurons and indirect modulation of prolactin release by serotonin. Patients taking antidepressants presenting to their clinician with symptoms potentially related to hyperprolactinaemia, such as galactorrhoea, should have their plasma prolactin level measured and their antidepressant changed if an increased prolactin level is confirmed. Routine monitoring of prolactin levels is otherwise not appropriate.
Literatur
1.
Zurück zum Zitat Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80(4): 1523–631PubMed Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80(4): 1523–631PubMed
2.
Zurück zum Zitat Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19(3): 225–68PubMedCrossRef Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19(3): 225–68PubMedCrossRef
3.
Zurück zum Zitat Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22(6): 724–63PubMedCrossRef Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22(6): 724–63PubMedCrossRef
4.
Zurück zum Zitat Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007; 3(5): 929–51PubMed Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007; 3(5): 929–51PubMed
5.
Zurück zum Zitat Leung A, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Physician 2004; 70(3): 543–50PubMed Leung A, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Physician 2004; 70(3): 543–50PubMed
6.
Zurück zum Zitat Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64(20): 2291–314PubMedCrossRef Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64(20): 2291–314PubMedCrossRef
7.
Zurück zum Zitat Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003; 349(21): 2035–41CrossRef Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003; 349(21): 2035–41CrossRef
9.
Zurück zum Zitat Holt RI. Medical causes and consequences of hyperprolactinaemia: a context for psychiatrists. J Psychopharmacol 2008; 22(2 Suppl. ): 28–37PubMedCrossRef Holt RI. Medical causes and consequences of hyperprolactinaemia: a context for psychiatrists. J Psychopharmacol 2008; 22(2 Suppl. ): 28–37PubMedCrossRef
10.
11.
Zurück zum Zitat Meltzer HY, Piyakalmala S, Schyve P, et al. Lack of effect of tricyclic antidepressants on serum prolactin levels. Psychopharmacology (Berl) 1977; 51(2): 185–7CrossRef Meltzer HY, Piyakalmala S, Schyve P, et al. Lack of effect of tricyclic antidepressants on serum prolactin levels. Psychopharmacology (Berl) 1977; 51(2): 185–7CrossRef
12.
Zurück zum Zitat Meltzer HY, Fang VS, Tricou BJ, et al. Effect of antidepressants on neuroendocrine axis in humans. Adv Biochem Psychopharmacol 1982; 32: 303–16PubMed Meltzer HY, Fang VS, Tricou BJ, et al. Effect of antidepressants on neuroendocrine axis in humans. Adv Biochem Psychopharmacol 1982; 32: 303–16PubMed
13.
Zurück zum Zitat Fava GA, Lisansky J, Buckman MT, et al. Prolactin, cortisol, and antidepressant treatment. Am J Psychiatry 1988; 145(3): 358–60PubMed Fava GA, Lisansky J, Buckman MT, et al. Prolactin, cortisol, and antidepressant treatment. Am J Psychiatry 1988; 145(3): 358–60PubMed
14.
Zurück zum Zitat Charney DS, Heninger GR, Sternberg DE. Serotonin function and mechanism of action of antidepressant treatment: effects of amitriptyline and desipramine. Arch Gen Psychiatry 1984; 41(4): 359–65PubMedCrossRef Charney DS, Heninger GR, Sternberg DE. Serotonin function and mechanism of action of antidepressant treatment: effects of amitriptyline and desipramine. Arch Gen Psychiatry 1984; 41(4): 359–65PubMedCrossRef
15.
Zurück zum Zitat Price LH, Charney DS, Delgado PL, et al. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan: serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 1989; 46(7): 625–31PubMedCrossRef Price LH, Charney DS, Delgado PL, et al. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan: serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 1989; 46(7): 625–31PubMedCrossRef
16.
Zurück zum Zitat Shapira B, Reiss A, Kaiser N, et al. Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. J Affect Disord 1989; 16(1): 1–4PubMedCrossRef Shapira B, Reiss A, Kaiser N, et al. Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. J Affect Disord 1989; 16(1): 1–4PubMedCrossRef
17.
Zurück zum Zitat Anderson IM, Cowen PJ. Clomipramine enhances prolactin and growth hormone responses to L-tryptophan. Psychopharmacology (Berl) 1986; 89(1): 131–3CrossRef Anderson IM, Cowen PJ. Clomipramine enhances prolactin and growth hormone responses to L-tryptophan. Psychopharmacology (Berl) 1986; 89(1): 131–3CrossRef
18.
Zurück zum Zitat Gadd EM, Norris CM, Beeley L. Antidepressants and galactorrhoea. Int Clin Psychopharmacol 1987; 2(4): 361–3PubMedCrossRef Gadd EM, Norris CM, Beeley L. Antidepressants and galactorrhoea. Int Clin Psychopharmacol 1987; 2(4): 361–3PubMedCrossRef
19.
Zurück zum Zitat Anand VS. Clomipramine-induced galactorrhoea and amenorrhoea. Br J Psychiatry 1985; 147: 87–8PubMedCrossRef Anand VS. Clomipramine-induced galactorrhoea and amenorrhoea. Br J Psychiatry 1985; 147: 87–8PubMedCrossRef
20.
Zurück zum Zitat Fowlie S, Burton J. Hyperprolactinaemia and nonpuerperal lactation associated with clomipramine [letter]. Scott Med J 1987; 32(2): 52PubMed Fowlie S, Burton J. Hyperprolactinaemia and nonpuerperal lactation associated with clomipramine [letter]. Scott Med J 1987; 32(2): 52PubMed
21.
Zurück zum Zitat Slater SL, Lipper S, Shiling DJ, et al. Elevation of plasmaprolactin by monoamine-oxidase inhibitors. Lancet 1977; 2(8032): 275–6PubMedCrossRef Slater SL, Lipper S, Shiling DJ, et al. Elevation of plasmaprolactin by monoamine-oxidase inhibitors. Lancet 1977; 2(8032): 275–6PubMedCrossRef
22.
Zurück zum Zitat Price LH, Charney DS, Heninger GR. Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 1985; 37(9): 809–18PubMedCrossRef Price LH, Charney DS, Heninger GR. Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 1985; 37(9): 809–18PubMedCrossRef
23.
Zurück zum Zitat Egberts AC, Meyboom RH, De Koning FH, et al. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol 1997; 44(3): 277–81PubMedCrossRef Egberts AC, Meyboom RH, De Koning FH, et al. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol 1997; 44(3): 277–81PubMedCrossRef
24.
Zurück zum Zitat Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152(1): 122–5PubMed Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152(1): 122–5PubMed
25.
Zurück zum Zitat Sagud M, Pivac N, Muck-Seler D, et al. Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 2002; 45(3): 139–43PubMedCrossRef Sagud M, Pivac N, Muck-Seler D, et al. Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 2002; 45(3): 139–43PubMedCrossRef
26.
Zurück zum Zitat Gordon C, Whale R, Cowen PJ. Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology 1998; 137(2): 201–2PubMedCrossRef Gordon C, Whale R, Cowen PJ. Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology 1998; 137(2): 201–2PubMedCrossRef
27.
Zurück zum Zitat Schlösser R, Wetzel H, Dorr H, et al. Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. Psychoneuroendocrinology 2000; 25(4): 377–88PubMedCrossRef Schlösser R, Wetzel H, Dorr H, et al. Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. Psychoneuroendocrinology 2000; 25(4): 377–88PubMedCrossRef
28.
Zurück zum Zitat Seifritz E, Baumann P, Muller MJ, et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males: a placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996; 14(4): 253–63PubMedCrossRef Seifritz E, Baumann P, Muller MJ, et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males: a placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996; 14(4): 253–63PubMedCrossRef
29.
Zurück zum Zitat Kapitany T, Schindl M, Schindler SD, et al. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 1999; 88(2): 75–88PubMedCrossRef Kapitany T, Schindl M, Schindler SD, et al. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 1999; 88(2): 75–88PubMedCrossRef
30.
Zurück zum Zitat Mondelli V, Gianotti L, Picu A, et al. Neuroendocrine effects of citalopram infusion in anorexia nervosa. Psychoneuroendocrinology 2006; 31(10): 1139–48PubMedCrossRef Mondelli V, Gianotti L, Picu A, et al. Neuroendocrine effects of citalopram infusion in anorexia nervosa. Psychoneuroendocrinology 2006; 31(10): 1139–48PubMedCrossRef
31.
Zurück zum Zitat Nadeem HS, Attenburrow MJ, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-HT-mediated neuroendocrine responses. Neuropsychopharmacology 2004; 29(9): 1699–703PubMedCrossRef Nadeem HS, Attenburrow MJ, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-HT-mediated neuroendocrine responses. Neuropsychopharmacology 2004; 29(9): 1699–703PubMedCrossRef
32.
Zurück zum Zitat Henning J, Netter P. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. Int J Neuropsychopharmacol 2002; 5(1): 67–71PubMed Henning J, Netter P. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. Int J Neuropsychopharmacol 2002; 5(1): 67–71PubMed
33.
Zurück zum Zitat Hawken ER, Owen JA, Van VD, et al. Effects of oral racemic citalopram on neuroendocrine responses. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(4): 694–700PubMedCrossRef Hawken ER, Owen JA, Van VD, et al. Effects of oral racemic citalopram on neuroendocrine responses. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(4): 694–700PubMedCrossRef
34.
Zurück zum Zitat Moeller O, Hetzel G, Rothermundt M, et al. Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment. J Psychiatr Res 2003; 37(3): 261–2PubMedCrossRef Moeller O, Hetzel G, Rothermundt M, et al. Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment. J Psychiatr Res 2003; 37(3): 261–2PubMedCrossRef
35.
Zurück zum Zitat Peterson MC. Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 2001; 76(2): 215–6PubMed Peterson MC. Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 2001; 76(2): 215–6PubMed
36.
Zurück zum Zitat Morrison J, Remick RA, Leung M, et al. Galactorrhea induced by paroxetine. Can J Psychiatry 2001; 46(1): 88–9PubMed Morrison J, Remick RA, Leung M, et al. Galactorrhea induced by paroxetine. Can J Psychiatry 2001; 46(1): 88–9PubMed
37.
Zurück zum Zitat Shim SH, Lee YJ, Lee EC. A case of galactorrhea associated with escitalopram. Psychiatry Investig 2009; 6: 230–2PubMedCrossRef Shim SH, Lee YJ, Lee EC. A case of galactorrhea associated with escitalopram. Psychiatry Investig 2009; 6: 230–2PubMedCrossRef
38.
Zurück zum Zitat Aggarwal A, Kumar R, Sharma RC, et al. Escitalopram induced galactorrhoea: a case report. Prog Neuropscyhopharmacol Biol Psychiatry 2010; 34: 557–8CrossRef Aggarwal A, Kumar R, Sharma RC, et al. Escitalopram induced galactorrhoea: a case report. Prog Neuropscyhopharmacol Biol Psychiatry 2010; 34: 557–8CrossRef
39.
Zurück zum Zitat Daffner-Bugia C, Laakmann G, Voderholzer U, et al. The neuroendocrine effects of venlafaxine in healthy subjects. Hum Psychopharmacol 1996; 11: 1–9CrossRef Daffner-Bugia C, Laakmann G, Voderholzer U, et al. The neuroendocrine effects of venlafaxine in healthy subjects. Hum Psychopharmacol 1996; 11: 1–9CrossRef
40.
Zurück zum Zitat Bhatia SC, Bhatia SK, Bencomo L. Effective treatment of venlafaxine-induced noncyclical mastalgia with bromocriptine. J Clin Psychopharmacol 2000; 20(5): 590–1PubMedCrossRef Bhatia SC, Bhatia SK, Bencomo L. Effective treatment of venlafaxine-induced noncyclical mastalgia with bromocriptine. J Clin Psychopharmacol 2000; 20(5): 590–1PubMedCrossRef
41.
42.
Zurück zum Zitat Ashton AK, Longdon MC. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants. Am J Psychiatry 2007; 164(7): 1121–2PubMedCrossRef Ashton AK, Longdon MC. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants. Am J Psychiatry 2007; 164(7): 1121–2PubMedCrossRef
43.
Zurück zum Zitat Schule C, Baghai T, Schmidbauer S, et al. Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 2004; 29(2): 185–200PubMedCrossRef Schule C, Baghai T, Schmidbauer S, et al. Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 2004; 29(2): 185–200PubMedCrossRef
44.
Zurück zum Zitat Laakmann G, Schule C, Baghai T, et al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999; 24: 769–84PubMedCrossRef Laakmann G, Schule C, Baghai T, et al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999; 24: 769–84PubMedCrossRef
45.
Zurück zum Zitat Schule C, Baghai T, Goy J, et al. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 2002; 163: 95–101CrossRef Schule C, Baghai T, Goy J, et al. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 2002; 163: 95–101CrossRef
46.
Zurück zum Zitat Laakmann G, Schule C, Baghai T, et al. Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion. J Clin Psychopharmacol 2000; 20: 101–3PubMedCrossRef Laakmann G, Schule C, Baghai T, et al. Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion. J Clin Psychopharmacol 2000; 20: 101–3PubMedCrossRef
47.
Zurück zum Zitat Schüle, Baghai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004; 79: 54–62PubMedCrossRef Schüle, Baghai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004; 79: 54–62PubMedCrossRef
48.
Zurück zum Zitat Laakmann G, Schule C, Baghai T, et al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999; 24(7): 769–84PubMedCrossRef Laakmann G, Schule C, Baghai T, et al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999; 24(7): 769–84PubMedCrossRef
49.
Zurück zum Zitat Schule C, Baghai T, Goy J, et al. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 2002; 163(1): 95–101CrossRef Schule C, Baghai T, Goy J, et al. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 2002; 163(1): 95–101CrossRef
50.
Zurück zum Zitat Laakmann G, Schule C, Baghai T, et al. Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion. J Clin Psychopharmacol 2000; 20(1): 101–3PubMedCrossRef Laakmann G, Schule C, Baghai T, et al. Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion. J Clin Psychopharmacol 2000; 20(1): 101–3PubMedCrossRef
51.
Zurück zum Zitat Schule C, Baghai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004; 79(1): 54–62PubMedCrossRef Schule C, Baghai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004; 79(1): 54–62PubMedCrossRef
52.
Zurück zum Zitat Whiteman PD, Peck AW, Fowle ASE, et al. Bupropion fails to affect plasma prolactin and growth hormone in normal subjects [letter]. Br J Clin Pharmacol 1982; 13(743): 745 Whiteman PD, Peck AW, Fowle ASE, et al. Bupropion fails to affect plasma prolactin and growth hormone in normal subjects [letter]. Br J Clin Pharmacol 1982; 13(743): 745
53.
Zurück zum Zitat Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. Am J Psychiatry 1993; 150(8): 1269–70PubMed Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. Am J Psychiatry 1993; 150(8): 1269–70PubMed
54.
58.
Zurück zum Zitat Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004; 29(5): 833–46PubMedCrossRef Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004; 29(5): 833–46PubMedCrossRef
59.
Zurück zum Zitat Rittenhouse PA, Levy AD, Li Q, et al. Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1C/2 receptors. Endocrinology 1993; 133(2): 661–7PubMedCrossRef Rittenhouse PA, Levy AD, Li Q, et al. Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1C/2 receptors. Endocrinology 1993; 133(2): 661–7PubMedCrossRef
60.
Zurück zum Zitat Jorgensen H, Knigge U, Warberg J. Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan. Neuroendocrinology 1992; 55(3): 336–43PubMedCrossRef Jorgensen H, Knigge U, Warberg J. Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan. Neuroendocrinology 1992; 55(3): 336–43PubMedCrossRef
61.
Zurück zum Zitat Sonino N, Tomba E, Fava GA. Psychosocial approach to endocrine disease. Adv Pharmacother 2007; 28: 21–33 Sonino N, Tomba E, Fava GA. Psychosocial approach to endocrine disease. Adv Pharmacother 2007; 28: 21–33
62.
Zurück zum Zitat Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57(5): 485–91PubMed Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57(5): 485–91PubMed
63.
Zurück zum Zitat Klein JJ, Segal RL, Warner RR. Galactorrhea due to imipramine: report of a case. N Engl J Med 1964; 271: 510–2PubMedCrossRef Klein JJ, Segal RL, Warner RR. Galactorrhea due to imipramine: report of a case. N Engl J Med 1964; 271: 510–2PubMedCrossRef
64.
Zurück zum Zitat Wolfsperger M, Greil W. Galactorrhea during treatment with trimipramine: a case report. Pharmacopsychiatry 2005; 38(6): 326–7PubMedCrossRef Wolfsperger M, Greil W. Galactorrhea during treatment with trimipramine: a case report. Pharmacopsychiatry 2005; 38(6): 326–7PubMedCrossRef
65.
Zurück zum Zitat Bonin B, Vandel P, Sechter D, et al. Paroxetine and galactorrhea. Pharmacopsychiatry 1997; 30(4): 133–4PubMedCrossRef Bonin B, Vandel P, Sechter D, et al. Paroxetine and galactorrhea. Pharmacopsychiatry 1997; 30(4): 133–4PubMedCrossRef
66.
Zurück zum Zitat Ghosal M, Mukhopadhyay S, Sanyal D. A case of paroxetine-inducted galactorrhoea. German J Psychiatry 2005; 8: 23–4 Ghosal M, Mukhopadhyay S, Sanyal D. A case of paroxetine-inducted galactorrhoea. German J Psychiatry 2005; 8: 23–4
67.
Zurück zum Zitat Davenport E, Velamoor R. A case of paroxetine-induced galactorrhea. Can J Psychiatry 2002; 47(9): 890–1PubMed Davenport E, Velamoor R. A case of paroxetine-induced galactorrhea. Can J Psychiatry 2002; 47(9): 890–1PubMed
68.
Zurück zum Zitat Gonzalez E, Minguez L, Sanguino RM. Galactorrhea after paroxetine treatment [letter]. Pharmacopsychiatry 2000; 33(3): 118PubMedCrossRef Gonzalez E, Minguez L, Sanguino RM. Galactorrhea after paroxetine treatment [letter]. Pharmacopsychiatry 2000; 33(3): 118PubMedCrossRef
69.
Zurück zum Zitat Yalug I, Tural U, Unsalan N, et al. Reboxetine may cause amenorrhea in female patients. Int J Psychiatry Clin Pract 2006; 10(3): 223–5CrossRef Yalug I, Tural U, Unsalan N, et al. Reboxetine may cause amenorrhea in female patients. Int J Psychiatry Clin Pract 2006; 10(3): 223–5CrossRef
70.
Zurück zum Zitat Gulsun M, Algul A, Semiz UB, et al. A case with euprolactinemic galactorrhea induced by escitalopram. Int J Psychiatry Med 2007; 37: 275–8PubMedCrossRef Gulsun M, Algul A, Semiz UB, et al. A case with euprolactinemic galactorrhea induced by escitalopram. Int J Psychiatry Med 2007; 37: 275–8PubMedCrossRef
Metadaten
Titel
Antidepressant-induced hyperprolactinaemia
incidence, mechanisms and management
verfasst von
Flora Coker
Prof. David Taylor
Publikationsdatum
01.07.2010
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 7/2010
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11533140-000000000-00000

Weitere Artikel der Ausgabe 7/2010

CNS Drugs 7/2010 Zur Ausgabe

Therapy in Practice

Lafora disease

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.